New Treatment Option for HER2-Positive Breast Cancer Offers Fewer Side Effects
A year of trastuzumab emtansine (T-DM1) may offer similar survival rates to standard chemotherapy for early-stage HER2-positive breast cancer, but with a distinct and potentially more manageable side-effect profile. This new approach provides patients and clinicians with another evidence-based option, prioritizing quality of life alongside survival.
Understanding HER2-Positive Breast Cancer
About one in five breast cancers are HER2-positive, meaning they are driven by an overactive protein that promotes tumor growth. Over the past two decades, targeted therapies against HER2, such as trastuzumab, have significantly improved outcomes for patients with this subtype of breast cancer.
The Evolution of Treatment: From Trastuzumab to T-DM1
Initially, a combination of trastuzumab and chemotherapy dramatically reduced cancer recurrence and death. For patients with small tumors that hadn’t spread to the lymph nodes, 12 weeks of paclitaxel plus trastuzumab, followed by trastuzumab alone, became a standard approach, achieving high 10-year survival rates.
However, paclitaxel is associated with side effects like nerve damage, hair loss, and reduced blood cell counts. As patients live longer thanks to improved treatments, minimizing these side effects has become increasingly important.
How T-DM1 Works
Trastuzumab emtansine (T-DM1) represents a more targeted approach. It combines trastuzumab with a chemotherapy drug, delivering treatment directly to HER2-positive cancer cells while limiting exposure to healthy tissues. T-DM1 has already shown efficacy in higher-risk, early-stage settings, and the ATEMPT trial investigated its potential to replace standard chemotherapy in lower-risk, stage I disease.
The ATEMPT Trial: Key Findings
The ATEMPT trial enrolled nearly 500 patients in the United States. Participants received either T-DM1 every three weeks for a year or the standard treatment of paclitaxel and trastuzumab. After three years, approximately 98% of patients receiving T-DM1 were alive and cancer-free, compared to 94% on standard therapy.
Overall rates of side effects were similar between the two groups (46% in the T-DM1 group and 47% in the standard therapy group). However, the types of side effects differed significantly. Patients receiving paclitaxel were more likely to experience nerve damage, hair loss, low white blood cell counts, infusion-related reactions, and diarrhea. T-DM1 more often caused low platelet counts and liver changes.
17% of patients stopped T-DM1 early due to side effects, compared to 6% on standard therapy. Many of those who discontinued T-DM1 continued treatment with trastuzumab alone.
Patients receiving T-DM1 reported less nerve damage, less hair loss, and better work productivity, particularly during the initial 12 weeks of treatment.
Implications for Patients and Clinicians
The ATEMPT trial doesn’t replace the current standard of care, but it expands the range of evidence-based options available. T-DM1 may be particularly beneficial for patients hoping to avoid nerve damage or hair loss. However, it’s more expensive and carries risks of liver problems and low platelet counts.
The study reflects a growing trend in oncology: treatment decisions are increasingly incorporating patient preferences, recognizing that quality of life is as important as survival.
The Future of HER2-Positive Breast Cancer Therapy
HER2-targeted therapy has dramatically improved outcomes for patients with HER2-positive breast cancer. Future research is exploring shorter courses of T-DM1 to maintain efficacy while reducing discontinuation rates and cost. Longer follow-up from the ATEMPT trial will further clarify the long-term benefits of this treatment approach. The goal is to continue improving both survival rates and the overall patient experience.